Exclusive Summary

• A monoclonal antibody with Best-in-class potential targeting IL-6R, featuring a unique pH-dependent binding mechanism (FcRn-mediated recycling) that delivers hundreds-fold higher affinity and 20-30 times greater activity than Tocilizumab.
• Demonstrated robust clinical efficacy in Phase II head-to-head trials, achieving an outstanding ACR70 response rate of 30.6% at 12 weeks in MTX-IR moderate-to-severe RA patients, significantly outperforming historical data of marketed biologics.
• Excellent safety and tolerability profile, with no Grade III or higher adverse events observed in Phase Ib/II RA clinical trials, offering a de-risked, late-stage Phase III-ready asset for partners.

Asset Materials

Contact Us for Full Materials